This is the worst cover of Penny Lane, I have ever heard.

Really important session by Come Bommier discussing burnout amongst haematologists #EHA2025 European Hematology Association

CONGRESS | #EHA2025 | PRESENTATION Shaji Kumar Shaji Kumar Mayo Clinic presents results from the phase II RedirecTT-1 trial of talquetamab + teclistamab in patients with RRMM with EMD. Tal + Tec led to an ORR of 78.9% and a ≥CR rate of 54.4%; efficacy exceeded standard therapies,

1/2 Many people living with myeloma experience symptoms for months or even years before receiving a diagnosis. By sharing this post, you can help raise awareness and make sure more people recognise the warning signs sooner ⚠️ #MyelomaAwarenessWeek #MyelomaWarningSigns

Somewhat strange to hear Nick Robinson haranguing an NHS Consultant for being on “over £100,000” and claiming to channel the feelings of ordinary people. His salary in 2024 was between £345,000 - £349,000. For presenting radio programs. Which never saved anyone’s life?

Breaking: Big news for smoldering myeloma. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of a new indication for DARZALEX®(daratumumab) subcutaneous (SC) formulation as monotherapy for the treatment

Nelson Mandela's World Cup moment was 30 years ago on Tuesday. Inequality hasn't shifted in South Africa but the magic of that day endures. My column for ⁦The Observer⁩ observer.co.uk/news/sport/art…

Improvement needed from Zak Crawley 👀

Trying to resurrect his career on Croatian tele? #GreggWallace

Do we need maintenance therapy for everyone in quadruplet era? particularly relevant for older adults with CEPHEUS and IMROZ results. lucky me that I got to write this with Luciano J Costa 😃 onlinelibrary.wiley.com/doi/full/10.10… McMaster University

Persuasive data. Lenalidomide often added for cycles 2 & 3 onwards after starting with DVD or D-CVD. Can't be done in the UK (yet). #mmsm Early daratumumab therapy improves renal outcomes in newly diagnosed patients with myeloma admitted with AKI ashpublications.org/bloodadvances/…

Two specific situations where belantamab can have a major impact are 1) Relapsed high tumor burden myeloma that is refractory to other myeloma drugs and where CART or bispeicifics will be too risky. Here even a few doses of belantamab to control myeloma can open up other

Phillies debut the “Coldplay Kiss Cam”. Wait for it…

Thanks to Robert Z. Orlowski for highlighting a further publication from the iTIMM study, led by Christina Messiou The Royal Marsden NHS Foundation Trust. MRD detected by whole body MRI clearly predictive of PFS post ASCT. Martin Kaiser

Just out! Current Risk stratification of all Plasma Cell Disorders. MGUS, SMM, Myeloma, Amyloidosis. We paid Open Access fees so you can download and read freely! Lots of Tables. Bookmark. Saurabh Zanwar Shaji Kumar Leukemia Journal Link: nature.com/articles/s4137…

🚨 NEWS 🚨 European Commission grants approval to subcutaneous daratumumab monotherapy for the treatment of high-risk smoldering #MultipleMyeloma; based on data from the phase III AQUILA study. This approval represents the first authorized treatment in this indication. Read more:

*runs to LinkedIn* WHAT CHRIS WOAKES BATTING WITH ONE ARM TAUGHT ME ABOUT B2B SOFTWARE SALES

#Myeloma Paper of the Day: Simultaneous whole-body multi-parametric 2-[18F]FDG-PET/MRI in smoldering myeloma assessment showing presence of diffuse BM involvement on MRI was the strongest adverse prognostic parameter for PFS to symptomatic myeloma: pubmed.ncbi.nlm.nih.gov/40775455/. #mmsm